beatandraise : SEC Filings Research with AI

beatandraise.com

2.2.0.25falsefalse001600 - Disclosure - Earnings Per Share Attributable to Common Shareholderstruefalsefalse1falsefalseUSDfalsefalse1/1/2011 - 4/3/2011 USD ($) USD ($) / shares $Cur_3mos_20110403http://www.sec.gov/CIK0000078003duration2011-01-01T00:00:002011-04-03T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDperShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PercentStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$2true0us-gaap_EarningsPerShareAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalseEarnings Per Share Attributable to Common Shareholders [Abstract]3false0us-gaap_EarningsPerShareTextBlockus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<div style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <div> <div style="display: block; text-indent: 0pt"> <a name="xbrlnote13">Note 13. Earnings Per Share Attributable to Common Shareholders</a> </div> <div style="display: block; text-indent: 0pt"> </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> Basic and diluted earnings per share (EPS) were computed using the following data: <div> <hr size="2" width="100%" align="left" style="COLOR: black"/> </div> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td style="padding-bottom: 2px" valign="bottom">   </td> <td style="padding-bottom: 2px" valign="bottom">   </td> <td style="border-bottom: black 2px solid" valign="bottom" colspan="6"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="center"> Three Months Ended </div> </td> <td style="border-bottom: black 2px solid" valign="bottom" align="left">   </td> </tr> <tr> <td style="border-bottom: black 2px solid" valign="bottom" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> (millions) </div> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="right">   </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> April 3, </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> 2011 </div> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="left">   </td> <td style="text-indent: 0pt; margin-left: 0pt; padding-bottom: 2px; MARGIN-RIGHT: 0pt" valign="bottom" align="right">   </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="right" colspan="2"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> April 4, </div> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="right"> 2010 </div> </td> <td style="text-indent: 0pt; border-bottom: black 2px solid; margin-left: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" align="left">   </td> </tr> <tr> <td valign="bottom">   </td> <td valign="bottom">   </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom" align="left">   </td> <td valign="bottom">   </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom" align="left">   </td> </tr> <tr> <td valign="bottom" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> EPS Numerator––Basic: </div> </td> <td valign="bottom">   </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom" align="left">   </td> <td valign="bottom">   </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Income from continuing operations </div> </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left"> $ </td> <td valign="bottom" width="9%" align="right"> 2,224 </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left"> $ </td> <td valign="bottom" width="9%" align="right"> 2,014 </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Less: Net income attributable to noncontrolling interests </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 12 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 9 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Income from continuing operations attributable to Pfizer Inc. </div> </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 2,212 </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 2,005 </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Less: Preferred stock dividends––net of tax </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> –– </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 1 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Income from continuing operations attributable to Pfizer Inc. common shareholders </div> </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 2,212 </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 2,004 </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Discontinued operations––net of tax </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 10 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 21 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 4px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Net income attributable to Pfizer Inc. common shareholders </div> </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> $ </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 2,222 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> $ </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 2,025 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> EPS Numerator––Diluted: </div> </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Income from continuing operations attributable to Pfizer Inc. common shareholders and </div> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left">  assumed conversions </div> </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left"> $ </td> <td valign="bottom" width="9%" align="right"> 2,212 </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left"> $ </td> <td valign="bottom" width="9%" align="right"> 2,005 </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> Discontinued operations––net of tax </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 10 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 21 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 4px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> Net income attributable to Pfizer Inc. common shareholders and assumed conversions </div> </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> $ </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 2,222 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left"> $ </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 2,026 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> EPS Denominator: </div> </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt" align="left"> Weighted-average number of common shares outstanding––Basic </div> </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 7,982 </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right"> 8,061 </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 2px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Common-share equivalents: stock options, stock issuable under employee </div> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left">  compensation plans and convertible preferred stock </div> </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 53 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 2px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 2px solid" valign="bottom" width="9%" align="right"> 40 </td> <td style="border-bottom: black 2px solid" valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="padding-bottom: 4px" valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Weighted-average number of common shares outstanding––Diluted </div> </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 8,035 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="padding-bottom: 4px" valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 8,101 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td valign="bottom" width="76%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" align="left">   </td> <td valign="bottom" width="9%" align="right">   </td> <td valign="bottom" width="1%" align="left">   </td> </tr> <tr> <td style="border-bottom: black 6px double " valign="bottom" width="76%" align="left"> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left"> Stock options that had exercise prices greater than the average market price of our </div> <div style="display: block; text-indent: -9pt; margin-left: 9pt; MARGIN-RIGHT: 0pt" align="left">  common stock issuable under employee compensation plans(a) </div> </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 290 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> <td style="border-bottom: black 6px double " valign="bottom" width="9%" align="right"> 366 </td> <td style="border-bottom: black 6px double " valign="bottom" width="1%" align="left">   </td> </tr> </table> </div> <div align="left"> <table width="100%" cellspacing="0" cellpadding="0" border="0" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="width: 36pt" width="2%"> <div style="text-indent: 0pt; margin-left: 0pt; MARGIN-RIGHT: 0pt"> (a) </div> </td> <td width="98%"> <div align="left"> These common stock equivalents were outstanding during the first quarters of 2011 and 2010, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. </div> </td> </tr> </table> </div> </div> </div>Note 13. Earnings Per Share Attributable to Common Shareholders Basic and dilutedfalsefalsefalsefalsefalseOthernonnum:textBlockItemTypenaThe entire disclosure for earnings per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 falsefalseEarnings Per Share Attributable to Common Shareholders [Text Block]12Earnings Per Share Attributable to Common ShareholdersUnKnownUnKnownUnKnownUnKnownfalsetrue